A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 618-632

  Vrou Offersen, Birgitte ^a   Alsner, Jan ^a   Ege Olsen, Karen ^b   Riisbro, Rikke ^c   Brünner, Nils ^c   Brandt Sørensen, Flemming ^a   Sandahl Sørensen, Boe ^a   Olrik Schlemmer, Birgitte ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; MIB1 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ANGIOGENESIS; ARTICLE; BREAST; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CELL ACTIVITY; CELL PROLIFERATION; DENATURING GRADIENT GEL ELECTROPHORESIS; DISEASE MARKER; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STAINING; TUMOR VOLUME; ADULT; AGED; BREAST TUMOR; CANCER STAGING; CELL GROWTH; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL GROWTH PROCESSES; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 45149114565     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801958295     Document Type: Article

References (21)

1. Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer 2005;6:61-76.
2. Erdem O, Dursun A, Coskun U, Gunel N. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori 2005;91:46-52.
3. Look M, van PW, Duffy M, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003;90:538-48.
4. Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer-relevance to prognosis. Acta Oncol 2002;41:695-703.
5. Offersen BV, Sørensen FB, Knoop A, Overgaard J. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology 2003;43:573-82.
6. Offersen BV, Riisbro R, Knoop A, Brunner N, Overgaard J. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. Acta Oncol 2007;46:782-91.
7. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998;58:2166-9.
8. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39:327-33.
9. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6:3923-31.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
11. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007.
12. Petitjean A, Achatz MI, Børresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.
13. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
14. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004;43:35-42.
15. Schlemmer BO, Sørensen BS, Overgaard J, Olsen KE, Gjerdrum LM, Nexø E. Quantitative PCR-new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization. Scand J Clin Lab Invest 2004;64:511-22.
16. Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998;106:371-7.
17. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
18. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369:29-36.
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
20. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
21. Alsner J , Jensen V , Overgaard J. A comparison among p53 expression and TP53 mutations as prognostic variables in tumours from 401 patients diagnosed with early breast cancer. Acta Oncol 2008;47:600-7.